Anchiano therapeutics ltd. (ANCN)
Income statement / Quarterly
Mar'20Mar'19
Operating expenses:
Research and development

1,050

4,135

General and administrative

1,825

1,291

Restructuring expense

670

-

Total operating expenses

3,545

5,426

Finance (income) expense, net

-10

4,487

Net loss and comprehensive loss

-3,535

-9,913

Basic and diluted loss per share

-0.10

-0.38

Weighted average number of shares outstanding - basic and diluted

37,099

26,337